This is the authors' abstract. We don't add key points for this paper.
Stiripentol is approved as an add-on therapy with clobazam and/or valproate for seizures associated with Dravet syndrome (DS). Evidence of stiripentol efficacy in other drug-resistant epilepsies is limited. This was a single-centre, retrospective, observational study of patients aged ≤ 15 years with non-Dravet epilepsy or DS who initiated stiripentol treatment in Spain. The study included 18 patients with DS and 17 with non-Dravet epilepsy; 76.5% of the latter had a developmental and epileptic encephalopathy. Median (range) age at stiripentol initiation was 52 (4–180) months. Three months of add-on stiripentol provided overall improvement in seizures (number, duration and/or intensity) for 76.5% of the non-Dravet and 61.1% of the DS patients (p = 0.30), all of whom were drug-resistant to prior antiseizure medications (ASMs). Stiripentol reduced seizure frequency by ≥ 50% in 58.8% of the non-Dravet patients and 44.4% of the DS cohort (p = 0.40); 20% of all patients became seizure-free. Stiripentol reduced all seizure types in both cohorts. Kaplan–Meier survival analysis found a higher probability of sustained stiripentol efficacy in the DS cohort (120 months) than the non-Dravet cohort (16 months; p = 0.012). Stiripentol improved cognition and Clinical Global Impression scale scores in approximately 60% of all patients; sleep improved for 19.2%. Acute stiripentol treatment (maximum dose 6.7–100 mg/kg/day) initiated in five patients (four with non-Dravet epilepsy and one with DS) during refractory status epilepticus (SE) successfully resolved SE over a median 0.5 days. Adverse events, mainly mild-to-moderate, occurred in 47.1% and 41.2% of patients in the non-Dravet and DS cohorts, respectively. Six patients (35.3%) with non-Dravet epilepsy discontinued ≥ 1 other ASMs after stiripentol initiation. Add-on stiripentol provides overall improvement in different seizure types and non-seizure manifestations for paediatric patients with drug-resistant epilepsy, including epileptic syndromes besides DS, and appeared effective in acute treatment of SE. Stiripentol was generally well tolerated. Stiripentol helps to control seizures (abnormal electrical activities in the brain) in people with Dravet syndrome (DS) who are already taking other antiseizure medications. DS begins in infancy and the seizures are hard to treat. To learn whether stiripentol helps patients with other hard-to-treat seizure disorders, this study reviewed the medical records of 35 children and adolescents (aged 4 months to 15 years) who started stiripentol treatment at a hospital in Spain. Eighteen patients had DS and 17 had other types of hard-to-treat seizures (i.e. non-Dravet epilepsy). Prior to starting stiripentol, many patients were experiencing multiple seizures daily, all had intellectual disabilities, and all had seizures that had not responded to several previous medications. After 3 months of stiripentol treatment, seizures were improved in two-thirds of the DS group and three-quarters of the non-Dravet epilepsy group. Stiripentol reduced seizure frequency by at least 50% in around half of all patients, improved many different seizure types, improved mental processes in around half of the patients, and sleep for around one-fifth. Importantly, stiripentol stopped prolonged seizure activity or repetitive seizures in five patients whose seizures had lasted for 2–45 days despite emergency treatments; stiripentol stopped seizures within a few hours or up to 14 days. Adverse events during stiripentol treatment were mainly mild-to-moderate. These results indicate that stiripentol effectively and safely reduces a broad range of seizure types, and provides a global improvement in children and adolescents with hard-to-treat epilepsy, including those with non-Dravet epilepsy or DS.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Insuga et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: